- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02002689
LDE225 for Patients With PTCH1 or SMO Mutated Tumors (SIGNATURE)
April 25, 2016 updated by: Novartis Pharmaceuticals
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- University of California Davis Cancer Center UC Davis Cancer (3)
-
-
Colorado
-
Greenwood Village, Colorado, United States
- Rocky Mountain Cancer Centers RMCC - Aurora
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Lurie Children's Hospital of Chicago Developmental Therapeutics
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Minnesota Oncology Hematology, P.A. Southdate Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation Cleveland Clinic (19)
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Sanford Research Sanford Health
-
-
Texas
-
Houston, Texas, United States, 77024
- Oncology Consultants Oncology Group
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
-
-
Utah
-
Murray, Utah, United States, 84157
- Intermountain Medical Center Intermountain Healthcare
-
-
Washington
-
Seattle, Washington, United States, 98109-1023
- Seattle Cancer Care Alliance Skagit Valley Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy (except CML, ALL and AML).
- Patient has pre-identified tumor with a PTCH1 or SMO mutation.
- Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
- Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Exclusion Criteria:
- Patients has received prior treatment with LDE225.
- Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis
- Patients has primary CNS tumor or CNS tumor involvement
- Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LDE225
LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
|
LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Overall Response (ORR) and Clinical Benefit (CBR)
Time Frame: 16 weeks
|
Clinical benefit rate (CBR) Number and percentage of subjects with CBR (responses of CR, PR or SD ≥ 16 weeks) as assessed by investigator was reported for all patients along with 95% exact confidence interval (CI).
Overall Response Rate (ORR) Overall response was to be determined by investigator assessment for each tumor in the study.
For subjects with solid tumors, the assessment criteria was RECIST 1.1 and included responses of CR and/or PR.
The number and percentage of subjects for different categories of overall response (e.g., for solid tumors - CR, PR, SD, PD, Not Evaluable) were to be provided for solid tumors, and each hematological tumor type (if applicable).
Ninety-five percent (95%) exact CI was to be provided for the response rate(s) (e.g., for solid tumors - CRn and/or PR) as well.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Timing and Estimated Rate for Progression-free Survival (PFS) - Full Analysis Set
Time Frame: 4 months
|
Progression-free survival (PFS) is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause within 30 days of last dose.
If a subject has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
|
4 months
|
Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
March 1, 2015
Study Completion (Actual)
March 1, 2015
Study Registration Dates
First Submitted
December 1, 2013
First Submitted That Met QC Criteria
December 1, 2013
First Posted (Estimate)
December 6, 2013
Study Record Updates
Last Update Posted (Estimate)
May 2, 2016
Last Update Submitted That Met QC Criteria
April 25, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLDE225XUS20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTCH1 or SMO Activated Solid and Hematologic Tumors
-
Endeavor Biomedicines, Inc.Active, not recruitingSolid Tumors With PTCH1 Loss-of-function MutationsUnited States
-
iOMEDICO AGBristol-Myers Squibb; Roche Pharma AGCompletedAdvanced Solid Tumors or Hematologic MalignanciesGermany
-
Ascentage Pharma Group Inc.RecruitingAdvanced Solid Tumors or Hematologic MalignanciesUnited States
-
University Hospital, Strasbourg, FranceRecruitingResistance to Activated Protein C in the Determination of Protein S ActivityFrance
-
Synta Pharmaceuticals Corp.CompletedLymphoma | Leukemia | Hematological Malignancies | Metastatic or Unresectable Solid TumorsUnited States
-
Mayo ClinicRecruitingSolid Tumors | Hematologic MalignanciesUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedSolid Tumors | Hematologic MalignanciesNetherlands
-
Merck Sharp & Dohme LLCRecruitingSolid Tumors | Hematologic MalignanciesUnited States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
-
Memorial Sloan Kettering Cancer CenterRecruiting
Clinical Trials on LDE225
-
Anne ChangNovartisCompletedBasal Cell CarcinomaUnited States
-
Novartis PharmaceuticalsCompletedTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome PatientsAustria, Switzerland
-
University of UtahWithdrawnPancreatic Ductal AdenocarcinomaUnited States
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionBelgium, Germany, Israel, Bulgaria, United States
-
Massachusetts General HospitalNovartisTerminatedGraft Versus Host DiseaseUnited States
-
Sun Pharmaceutical Industries LimitedActive, not recruitingBasal Cell CarcinomaSpain, Germany, Italy, Switzerland
-
Novartis PharmaceuticalsCompletedMedulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor CancersSpain, Switzerland, United Kingdom, United States
-
Novartis PharmaceuticalsCompletedMedulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor CancersTaiwan, Hong Kong, Japan
-
Novartis PharmaceuticalsCompletedNevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin SyndromeBelgium, Austria, Germany, Canada
-
Novartis PharmaceuticalsCompletedBasal Cell CarcinomaFrance, Italy, Germany, Hungary, United Kingdom, United States, Spain, Belgium, Switzerland, Australia, Canada, Greece